Successful Treatment of a Mesangial Proliferative Glomerulonephritis with Interstitial Nephritis Associated with Castleman's Disease by an Anti-interleukin-6 Receptor Antibody (Tocilizumab)

DOI Web Site PubMed 4 Citations 8 References Open Access
  • Otani Naoko
    Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan
  • Morishita Yoshiyuki
    Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan
  • Oh Iekuni
    Division of Hematology, Department of Internal Medicine, Jichi Medical University, Japan
  • Saito Osamu
    Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan
  • Takemoto Fumi
    Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan
  • Muto Shigeaki
    Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan
  • Kusano Eiji
    Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan

Search this article

Description

We report a case of mesangial proliferative glomerulonephritis with interstitial nephritis associated with multicentric Castleman's disease (MCD) successfully treated with an anti-interleukin-6 receptor antibody (tocilizumab). This mesangial proliferative glomerulonephritis with interstitial nephritis was resistant to methylprednisolone treatment; however, it was markedly improved with tocilizumab, which was administered intravenously at a dose of 8 mg/kg every 2 weeks. These results suggest that tocilizumab is effective for the treatment of mesangial proliferative glomerulonephritis with interstitial nephritis associated with MCD.<br>

Journal

  • Internal Medicine

    Internal Medicine 51 (11), 1375-1378, 2012

    The Japanese Society of Internal Medicine

Citations (4)*help

See more

References(8)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top